UTIs Diagnosed with Genetic Analysis of Cell-Free DNA
By LabMedica International staff writers Posted on 03 Jul 2018 |
Image: Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) shown between white blood cells in urinary microscopy. These changes are indicative of a urinary tract infection (Photo courtesy of Wikimedia Commons).
Genetic analysis of cell-free DNA (cfDNA) in urine samples reveals valuable information, which enables comprehensive monitoring of host and pathogen dynamics in bacterial and viral urinary tract infections.
Investigators at Cornell University (Ithaca, NY, USA) isolated cfDNA from 141 urine samples from a cohort of 82 kidney transplant recipients and performed next-generation sequencing.
The analysis revealed that urinary cfDNA was highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection. These different layers of information were accessible from a single assay and individually agreed with corresponding clinical tests based on quantitative PCR, conventional bacterial culture, and urinalysis. Furthermore, cfDNA revealed the frequent occurrence of diseases that remained undiagnosed with conventional diagnostic protocols.
“We found that we could deduce the fraction of the bacterial population that is growing, by carefully looking at the places in the genome where the cell-free DNA was derived from” said senior author Dr. Iwijn De Vlaminck, professor of biomedical engineering at Cornell University. "Metagenomic analysis of the cell-free DNA can also be used to infer which antimicrobial drugs may work best against a particular infection."
The paper describing genetic analysis of cell-free DNA in urine specimens was published in the June 20, 2018, online edition of the journal Nature Communications.
Related Links:
Cornell University
Investigators at Cornell University (Ithaca, NY, USA) isolated cfDNA from 141 urine samples from a cohort of 82 kidney transplant recipients and performed next-generation sequencing.
The analysis revealed that urinary cfDNA was highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection. These different layers of information were accessible from a single assay and individually agreed with corresponding clinical tests based on quantitative PCR, conventional bacterial culture, and urinalysis. Furthermore, cfDNA revealed the frequent occurrence of diseases that remained undiagnosed with conventional diagnostic protocols.
“We found that we could deduce the fraction of the bacterial population that is growing, by carefully looking at the places in the genome where the cell-free DNA was derived from” said senior author Dr. Iwijn De Vlaminck, professor of biomedical engineering at Cornell University. "Metagenomic analysis of the cell-free DNA can also be used to infer which antimicrobial drugs may work best against a particular infection."
The paper describing genetic analysis of cell-free DNA in urine specimens was published in the June 20, 2018, online edition of the journal Nature Communications.
Related Links:
Cornell University
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing